Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
Stefano Cascinu(Vita-Salute San Raffaele University), Rossana Berardi(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente), Monica Ronzoni, Francesca Galli(University of Modena and Reggio Emilia), Pietro Sozzi(Ospedale degli Infermi), Francesco Leone(Candiolo Cancer Institute), Monica Giordano(Ospedale Sant'Anna), Vittorina Zagonel(Istituto Oncologico Veneto), Stefania Mosconi(Ospedale Papa Giovanni XXIII), Felice Pasini(Ospedale Civile Di Ivrea), Antonio Nuzzo(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Davide Poli(Mario Negri Institute for Pharmacological Research), M Scartozzi(University of Cagliari), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Adriana Romiti(Sapienza University of Rome), Luca Gianni(Fondazione Michelangelo), Irene De Simone(Mario Negri Institute for Pharmacological Research), Guglielmo Nasti, F Ferraù(University of Bergamo), Fabio Galli(Mario Negri Institute for Pharmacological Research), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Roberto Labianca(University of Bergamo), R. V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaele Venezia(Ospedale "Floraspe Renzetti"), Valter Torri(Mario Negri Institute for Pharmacological Research), Domenico C. Corsi(Ospedale Papa Giovanni XXIII), Domenico C. Corsi(Fondazione Vincenzo Pansadoro), Massimo Aglietta(Candiolo Cancer Institute), Sara Lonardi(Istituto Oncologico Veneto), G. Rangoni(Ospedale degli Infermi), Alberto Zaniboni(Azienda Ospedaliera Sant'Andrea), Gerardo Rosati(Ospedale San Carlo)
Cited by 30
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k